Press Releases on September 24, 2018 - EIN Presswire - Press Release Distribution Service

Published on September 24, 2018 - 18:47 GMT

Human medicines European public assessment report (EPAR): Alunbrig, brigatinib, Carcinoma, Non-Small-Cell Lung, Date of ...

The most common side effects with Alunbrig (which may affect more than 1 in 4 people) are hyperglycaemia (high blood sugar levels), hyperinsulinaemia (high blood insulin levels), anaemia (low red blood cell counts), nausea (feeling sick), low white blood …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 24, 2018 - 18:47 GMT

Human medicines European public assessment report (EPAR): Alunbrig, brigatinib, Carcinoma, Non-Small-Cell Lung, Date of ...

The most common side effects with Alunbrig (which may affect more than 1 in 4 people) are hyperglycaemia (high blood sugar levels), hyperinsulinaemia (high blood insulin levels), anaemia (low red blood cell counts), nausea (feeling sick), low white blood …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 24, 2018 - 18:47 GMT

Human medicines European public assessment report (EPAR): Fulphila, pegfilgrastim, Neutropenia, Date of authorisation: 20/11/2018, ...

Fulphila is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections. It is given specifically to …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 24, 2018 - 18:47 GMT

Human medicines European public assessment report (EPAR): Fulphila, pegfilgrastim, Neutropenia, Date of authorisation: 20/11/2018, ...

Fulphila is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections. It is given specifically to …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 24, 2018 - 18:47 GMT

Human medicines European public assessment report (EPAR): Luxturna, voretigene neparvovec, Leber Congenital Amaurosis;Retinitis ...

Luxturna is a medicine that is used to treat adults and children with loss of vision due to inherited retinal dystrophy, a rare genetic disorder of the retina (the light sensitive membrane at the back of the eye). Luxturna can only be used while patients …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 24, 2018 - 18:47 GMT

Human medicines European public assessment report (EPAR): Luxturna, voretigene neparvovec, Leber Congenital Amaurosis;Retinitis ...

Luxturna is a medicine that is used to treat adults and children with loss of vision due to inherited retinal dystrophy, a rare genetic disorder of the retina (the light sensitive membrane at the back of the eye). Luxturna can only be used while patients …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 24, 2018 - 18:47 GMT

Human medicines European public assessment report (EPAR): Jivi, damoctocog alfa pegol, Hemophilia A, Date of authorisation: 22/11/...

The most common side effect with Jivi (which may affect more than 1 in 10 people) is headache. Hypersensitivity (allergic) reactions are common with Jivi (affecting up to 1 in 10 people) and may include swelling, burning and stinging at the injection site, …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 24, 2018 - 18:47 GMT

Human medicines European public assessment report (EPAR): Jivi, damoctocog alfa pegol, Hemophilia A, Date of authorisation: 22/11/...

The most common side effect with Jivi (which may affect more than 1 in 10 people) is headache. Hypersensitivity (allergic) reactions are common with Jivi (affecting up to 1 in 10 people) and may include swelling, burning and stinging at the injection site, …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 24, 2018 - 18:47 GMT

Human medicines European public assessment report (EPAR): Pifeltro, doravirine, HIV Infections, Date of authorisation: 22/11/2018, ...

Pifeltro is an antiviral medicine used to treat adults and adolescents from 12 years of age weighing at least 35 kg who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). Pifeltro …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 24, 2018 - 18:47 GMT

Human medicines European public assessment report (EPAR): Pifeltro, doravirine, HIV Infections, Date of authorisation: 22/11/2018, ...

Pifeltro is an antiviral medicine used to treat adults and adolescents from 12 years of age weighing at least 35 kg who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). Pifeltro …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 24, 2018 - 18:47 GMT

Human medicines European public assessment report (EPAR): Ziextenzo, pegfilgrastim, Neutropenia, Date of authorisation: 22/11/2018,...

Ziextenzo is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections. It is given specifically to …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 24, 2018 - 18:47 GMT

Human medicines European public assessment report (EPAR): Ziextenzo, pegfilgrastim, Neutropenia, Date of authorisation: 22/11/2018,...

Ziextenzo is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections. It is given specifically to …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 24, 2018 - 18:46 GMT

RadNet, Inc. to Present at the Sidoti & Company Fall 2018 Conference on Thursday, September 27th

LOS ANGELES, Sept. 24, 2018 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced …

Distribution channels: Conferences & Trade Fairs, Healthcare & Pharmaceuticals Industry ...

Published on September 24, 2018 - 18:40 GMT

Ziyen Inc. - Round 2 of Funding Closing: Regulation A+, Company Milestones and upcoming valuation change for the company

SAN DIEGO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Ziyen Inc., a Scottish American Oil and Energy Company, is about to close Round 2 of Funding as the company continues to execute the Regulation A+ process with a targeted IPO in 2019. This new type of initial …

Distribution channels: IT Industry ...

Published on September 24, 2018 - 18:38 GMT

MEDIA ADVISORY

Toronto, Sept. 24, 2018 (GLOBE NEWSWIRE) -- September 24, 2018 (Toronto) – The Investment Funds Institute of Canada (IFIC) and Pollara Strategic Insights will release the results of their 13TH annual survey of mutual fund investors on Thursday, September …

Distribution channels:

Published on September 24, 2018 - 18:36 GMT

King & Spalding Adds Peter Hsiao to its Environmental Team in Los Angeles

LOS ANGELES, Sept. 24, 2018 (GLOBE NEWSWIRE) -- King & Spalding today announced that Peter Hsiao has joined the Government Matters practice group as a partner in the Los Angeles office. As a member of the firm’s Environmental, Health and Safety team, …

Distribution channels: Technology ...

Published on September 24, 2018 - 18:30 GMT

Euro Manganese Inc. Files Final Prospectus and Announces Initial Public Offerings in Canada and Australia

VANCOUVER, British Columbia, Sept. 24, 2018 (GLOBE NEWSWIRE) -- THIS NEWS RELEASE MAY NOT BE DISTRIBUTED IN THE UNITED STATES OR DISSEMINATED OVER UNITED STATES NEWSWIRE SERVICES Euro Manganese Inc. ("EMN" or the "Company") today …

Distribution channels: Banking, Finance & Investment Industry, Mining Industry ...

Published on September 24, 2018 - 18:28 GMT

NYC ArtTech + Blockchain Connect 2018

NYC ArtTech + Blockchain Connect 2018 NEW YORK, NEW YORK , USA, September 24, 2018 /⁨EINPresswire.com⁩/ -- The New Art Academy is proud to announce a daylong symposium dedicated to understanding the role that technology, especially blockchain, is playing …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on September 24, 2018 - 18:27 GMT

Bank7 Corp. Announces Closing of Initial Public Offering of Common Stock

OKLAHOMA CITY, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Bank7 Corp., the bank holding company for Bank7, today announced that it has completed its initial public offering of 3,400,000 shares of its common stock at a price to the public of $19.00 per share, 2,900 …

Distribution channels: Banking, Finance & Investment Industry

Published on September 24, 2018 - 18:26 GMT

World Conference on Lung Cancer Monday Press Conference: Clinical Research Results and Gender Differences in Lung Cancer Survival

TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- At today’s press conference at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC), conference co-president Dr. Andrea Bezjak, M.D., FRCPC, MSc, …

Distribution channels: Healthcare & Pharmaceuticals Industry ...